AI
Entries for the Femtech World AI Innovation Award close this Friday
Entries for the Femtech World AI Innovation Award close this Friday at 4pm BST.
Now in its third year, the Femtech World Awards recognise the best examples of leadership, innovation and impact across women’s health.
The AI Innovation category, introduced in 2025, honours an individual or organisation pioneering the use of AI to transform women’s health outcomes.
The award is sponsored by Women’s Health Week, whose flagship women’s health conferences across Europe and the USA unite the complete ecosystem.
This includes visionary founders, strategic investors, multinational corporations, and specialised service providers – accelerating life-changing solutions that address women’s most critical unmet health needs.
To win the award, you’ll need to have demonstrated groundbreaking progress in applying AI to improve diagnosis, treatment accessibility or overall health outcomes for women, pushing the boundaries of what’s possible to create a more inclusive and equitable healthcare future.
The award is open to startups and established companies alike, whether you’re early-stage or scaled, UK-based or a global entrant.
If your technology uses AI to address any aspect of women’s health, you’re eligible to enter.
The Femtech World Awards are completely free to enter.
Whether you win or are shortlisted, you’ll receive extensive coverage across all Femtech World platforms.
Winners also receive a trophy and the chance to be interviewed by the Femtech World team.
Learn more about the awards and enter for free here.
Artificial intelligence is transforming women’s health at a pace and scale that would have seemed impossible a decade ago.
If you are building in this space, your work matters – and the AI Innovation Award exists to make sure the world knows it.
This award honours an individual or organisation pioneering the use of artificial intelligence to transform women’s health.
The winner will have demonstrated groundbreaking innovation in applying AI to improve diagnosis, treatment accessibility, or overall health outcomes for women.
This award celebrates those who are pushing the boundaries of AI to create a more inclusive, effective and equitable healthcare future for women.
Who Should Enter?
The AI Innovation Award is open to startups and established companies, early-stage products and scaled solutions, UK-based organisations and global entrants.
If your technology uses artificial intelligence to address any aspect of women’s health – reproductive health, maternal care, menopause, mental health, chronic conditions or beyond – you are eligible.
You do not need to have won awards before. You do not need a large team or significant revenue.
What you need is an innovation that is making a difference and the willingness to step forward and say so.
Judges are looking for impact, ingenuity and potential – not polish.
Enter Now
The Femtech World Awards are free to enter. And whether you win or are shortlisted you will receive extensive coverage across all Femtech World platforms.
Winners will also be sent a Femtech World Awards trophy and will have the opportunity to be interviewed by one of the team.
To find out more about the awards and see the full list of categories, head over to the entry page here.
GE HealthCare has secured US FDA authorisation for Pristina Recon DL, an AI tool that sharpens 3D mammogram images to support breast cancer detection.
Breast cancer is one of the most common cancers in women, with around one in eight expected to receive a diagnosis in their lifetime and more than a million deaths projected each year by 2050.
The newly authorised Pristina Recon DL sits on GE HealthCare’s Pristina Via system and is designed to improve image quality in digital breast tomosynthesis, a type of 3D mammography created from multiple X-ray images of the breast.
The technology uses deep learning, a form of artificial intelligence that learns patterns from large datasets, together with an approach known as iterative reconstruction, which repeatedly refines images to reduce noise and improve clarity.
According to GE HealthCare, Pristina Recon DL uses two deep learning models in sequence. One focuses on separating the useful signal in the image from background noise, while the second is trained to highlight clinically important details in a synthesised 2D view.
The company says it is the first mammography technology to combine deep learning with iterative reconstruction in this way, aiming to provide high-quality 3D images without increasing the radiation dose to patients.
Pristina Recon DL was born out of a deep commitment to our customers, listening closely to their feedback and working hand-in-hand with radiologists to enhance image quality and clarity,” said Jyoti Gupta, president and CEO, women’s health and X-ray at GE HealthCare. By applying advanced deep learning technologies, we’re shaping the future of breast imaging, one defined by uncompromised image quality, faster workflows and greater confidence in early cancer detection.”
In a recent study cited by the company, breast radiologists reportedly preferred the overall image quality of Pristina Recon DL in 99.1 per cent of image reviews when compared with a previous reconstruction method.
GE HealthCare also reports better performance for detecting microcalcifications, tiny deposits of calcium that can be an early sign of breast cancer, and breast masses in trials using modelled clinical data.
“Our collaboration with GE HealthCare has been instrumental in advancing breast imaging capabilities, and the new 3D image quality represents a meaningful upgrade that will benefit radiologists and patients alike,” said Dr Howard Berger, president and chief executive officer of RadNet. “This pioneering AI technology will help elevate breast care by delivering the clarity and consistency radiologists need to enable more confident diagnoses.”
The Pristina Via system with Recon DL is also marketed as offering workflow efficiencies, including automated image acquisition and personalised exam protocols designed to speed up appointments and reduce waiting times.
GE HealthCare highlights other features such as patient-assisted compression, which allows women to help adjust the pressure on the breast during imaging, with the aim of improving comfort and reducing anxiety.
Additional applications include a shortened biopsy workflow and contrast enhanced mammography, where a dye is injected to help highlight abnormal blood vessels. The company says diagnostic accuracy with its SenoBright HD contrast enhanced mammography is comparable to breast MRI in multiple studies.
“With Pristina Via with Recon DL, we’re setting a new benchmark in breast imaging, delivering sharper, clearer and more consistent images that empower radiologists with more confidence,” said Pooja Pathak, vice president and general manager, mammography at GE HealthCare. “As an upgradable feature on the Pristina Via platform, we are excited to now offer customers uncompromised image quality combined with fast, accurate workflows.”
GE HealthCare said it worked with academic centres and high-volume outpatient imaging sites to develop and validate the algorithms behind Pristina Recon DL, aiming to make it harder for early cancers to be missed on screening images.
Entrepreneur2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
News4 weeks agoLuna and Kindbody partner to bring data-driven insight to women’s health and fertility care
News4 weeks agoFemtech World Awards announces deadline extension
Wellness4 weeks agoMenstruation costs £20,359 a lifetime, sparking calls for Government action
Menopause3 weeks agoCalifornia plans US$3.4m menopause care overhaul
News4 weeks agoHalogen Ventures surpasses 100 investments in female-founded startups
Opinion4 weeks agoIndia’s top court rejects menstrual leave petition
Menopause3 weeks agoWatchdog bans five ads for women’s heath claims